A randamized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of oral administration of probiotic LKM512 in individuals with pre-arteriosclerosis

Autores [No se listan los autores]
Categoría Estudio primario
Registro de estudiosUMIN Clinical Trials Registry
Año 2013
Enlaces

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias

INTERVENTION:

The volunteer were given an 12‐week treatment with oral administration of bifidobacteria LKM512 powder (10 billion bacterial cells/package) two times per day. The volunteer were given an 12‐week treatment with oral administration of placebo powder without bifidobacteria LKM512 two times per day.

CONDITION:

Patients with high levels of serum triglyceride

PRIMARY OUTCOME:

Inflammation‐related markers (CoQ10, adiponectine, ICAM‐a, TNF‐alpha, s‐LOX, LAB)

INCLUSION CRITERIA:

Outpatients whose serum triglyceride level is 100 to 250 mg/dL
Epistemonikos ID: fcfc5c2911f932b7931f807bf5f0b7ff8258f2b5
First added on: Aug 22, 2024